Peter C. Mohr

Peter C. Mohr

Buxtehude, NI, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 180 publications

Evaluating the potential of candidate surrogate endpoints for overall survival in treatment-naive metastatic melanoma treated with anti-PD-1-based regimens with or without anti-CTLA-4 therapy.

Evaluating the potential of candidate surrogate endpoints for overall survival in treatment-naive metastatic melanoma treated with anti-PD-1-based regimens with or without anti-CTLA-4 therapy.

Journal: Journal for immunotherapy of cancer

Published: August 10, 2026

Robotically equipped 3D hybrid operating room in spine and trauma surgery - updated experience in 359 patients and 2080 screws.

Robotically equipped 3D hybrid operating room in spine and trauma surgery - updated experience in 359 patients and 2080 screws.

Journal: Journal of robotic surgery

Published: July 17, 2026

Real-world data on anti-PD-1 plus lenvatinib as a treatment option in pretreated advanced melanoma patients - a retrospective DeCOG study.

Real-world data on anti-PD-1 plus lenvatinib as a treatment option in pretreated advanced melanoma patients - a retrospective DeCOG study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: January 25, 2026

Treatment patterns in geriatric patients with melanoma and the effect of age on the efficacy of immunotherapy: Analysis from the real-world multicenter registry ADOREG.

Treatment patterns in geriatric patients with melanoma and the effect of age on the efficacy of immunotherapy: Analysis from the real-world multicenter registry ADOREG.

Journal: European journal of cancer (Oxford, England : 1990)

Published: January 16, 2026

Translating ctDNA into cutaneous melanoma care: An international expert survey.

Translating ctDNA into cutaneous melanoma care: An international expert survey.

Journal: European journal of cancer (Oxford, England : 1990)

Published: January 13, 2026

COMBI-EU: Real-World Evidence on Adverse Event Management and Time on Therapy with Adjuvant Dabrafenib Plus Trametinib in Patients with BRAF V600-Mutant Melanoma.

COMBI-EU: Real-World Evidence on Adverse Event Management and Time on Therapy with Adjuvant Dabrafenib Plus Trametinib in Patients with BRAF V600-Mutant Melanoma.

Journal: Cancers

Published: January 13, 2026

Enhanced overall and progression-free survival in advanced melanoma patients undergoing targeted therapy alongside antithrombotic treatment - Insights from a multicenter study involving 1296 patients from the prospective skin cancer registry ADOReg.

Enhanced overall and progression-free survival in advanced melanoma patients undergoing targeted therapy alongside antithrombotic treatment - Insights from a multicenter study involving 1296 patients from the prospective skin cancer registry ADOReg.

Journal: European journal of cancer (Oxford, England : 1990)

Published: October 12, 2025

Characteristics and quality of life of nine-year survivors with metastatic melanoma treated with pembrolizumab beyond second-line therapy.

Characteristics and quality of life of nine-year survivors with metastatic melanoma treated with pembrolizumab beyond second-line therapy.

Journal: European journal of cancer (Oxford, England : 1990)

Published: October 10, 2025

Slow breathing impacts inter-organ dynamics modulating brain function and risk behavior.

Slow breathing impacts inter-organ dynamics modulating brain function and risk behavior.

Journal: Neuron

Published: October 07, 2025

Correction: Hassel et al. Medical Needs and Therapeutic Options for Melanoma Patients Resistant to Anti-PD-1-Directed Immune Checkpoint Inhibition. Cancers 2023, 15, 3448.

Correction: Hassel et al. Medical Needs and Therapeutic Options for Melanoma Patients Resistant to Anti-PD-1-Directed Immune Checkpoint Inhibition. Cancers 2023, 15, 3448.

Journal: Cancers

Published: September 18, 2025

Tertiary lymphoid structures in Merkel cell carcinoma facilitate naïve and central memory T-cell infiltration linked to immunotherapy response.

Tertiary lymphoid structures in Merkel cell carcinoma facilitate naïve and central memory T-cell infiltration linked to immunotherapy response.

Journal: Journal for immunotherapy of cancer

Published: August 24, 2025

Melanoma of unknown primary shows an oncogenic pattern and clinical course of sun-exposed melanoma.

Melanoma of unknown primary shows an oncogenic pattern and clinical course of sun-exposed melanoma.

Journal: The British journal of dermatology

Published: August 06, 2025

Showing 1-12 of 180

Last Updated: 09/26/2026